In Itzykson’s study, azacitidine conferred a better response rate on patients with myelodysplastic syndromes and low blast count AML, which showed TET2 mutations’ predictive value of response to hypomethylated agents [34]. This evidence concerns the gene TET2 and myelodysplastic syndrome.